熊去氧胆酸治疗婴儿胆汁淤积症疗效观察

摘要

Objective To observe the clinical efficacy ofursodeoxycholic acid (UDCA) in the treatment of infantile cholestasis.Methods 72 1-6 months infants with cholestasis were randomly divided into an observation group and a control group,36 cases for each group.Both groups were routinely and liver-protectively treated;in addition,the observation group orally took UDCA.The symptoms,signs,and liver biochemical indicators were compared between these two groups before and after the treatment.The extended medication times were observed.Results One week after medication,the total effective rate was 58.33％ in the observation group and 38.89％ in the control group,with a statistical difference (P ＜0.05).Two weeks after medication,the total effective rate was 86.11％ in the observation group and 52.78％ in the control group,with a statistical difference (P ＜0.01).No significant adverse reactions occurred in both groups during the observation period.Conclusions Orally taking UDCA in the treatment of infantile cholestasis is effective and has few side effects,so it is worth being clinically generalized.%目的 观察熊去氧胆酸(UDCA)口服治疗婴儿胆汁淤积症的临床疗效.方法 将72例1～6月婴儿胆汁淤积症患儿随机分为观察组和对照组,各36例.两组都进行常规护肝治疗,观察组在常规护肝治疗基础上增加熊去氧胆酸口服,对两组治疗前后症状体征和肝生化指标的改善程度进行比较,并对延长服药时间疗效的变化进行观察.结果 观察组服药1周总有效率为58.33％,对照组总有效率为38.89％,两组疗效比较,差异有统计学意义(P＜0.05);服药2周观察组总有效率为86.11％,对照组总有效率为52.78％,治疗后两组疗效比较,差异有统计学意义(P＜0.01),观察期间两组未见明显不良反应.结论 熊去氧胆酸口服治疗婴儿胆汁淤积症疗效好,副作用少,可以在临床上推广使用.